Kaku K, et al. - In this two-part, double-blind, double-dummy, randomized, placebo-controlled trial (83 sites), researchers tested the safety as well as the efficacy of empagliflozin (Empa) 10 or 25 mg and linagliptin (Lina) 5 mg fixed-dose combinations (FDCs) in Japanese patients with type 2 diabetes mellitus (T2DM) poorly controlled with Empa. Findings revealed that the change from baseline in HbA1c at Week 24 was greater with Empa/Lina than with Empa/placebo (Plc). For Japanese patients with T2DM requiring combination therapy, Empa/Lina FDC was considered as a potential option.